Skip to main content
Publications
Rebordosa C , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia-Esteban R , Plana E , Tormos A , Farsani SF, Perez-Gutthann S , Pladevall-Vila M . Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts . Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Anthony MS , Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B , Beachler DC, Crowe CL, Johannes CB , Juhaeri J, Lanes S, Pan C, Rothman KJ , Saltus CW , Walsh KE. Risk of anaphylaxis among new users of glp-1 receptor agonists: a cohort study . Diabetes Care. 2024 Apr 1;47(4):712-9. doi: 10.2337/dc23-1911
Oberprieler NG, Kovesdy CP, Layton JB , Gay A, Farjat AE, Liu F, Johannes CB , Pladevall-Vila M , Vizcaya D. Early use and effectiveness of finerenone in US patients with CKD and type 2 diabetes: a FOUNTAIN platform analysis . Poster presented at the Kidney Week 2023; November 2, 2023. Philadelphia, PA.
Tormos A , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia Esteban R , Plana E , Farsani SF, Perez-Gutthann S , Pladevall-Vila M , Rebordosa C . Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D) . Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687
Thomsen RW, Andersen IT, Kristensen FP, Munch PV, Pladevall-Vila M , Johannes C , Saigi-Morgui N , Ziemiecki R , Layton J , Vizcaya D, Gay A, Farjat A, Liu F, Oberprieler N, Christiansen CF. Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and type 2 diabetes in Denmark: a nationwide population-based study part of the FOUNTAIN platform . Presented at the 59th Annual Meeting European Association for the Study of Diabetes (EASD) 2023; October 4, 2023. Hamburg, Germany.
Anthony MS , Djebarri L, Beachler DC, Aroda VR, Calingaert B , Pan C, Crowe C, Lanes S, Rothman KJ , Saltus CW , Berreghis S, Parlett LE, Bocage C, Walsh KE, Juhaeri J, Johannes C . Risk of anaphylaxis among new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) . Poster presented at the American Diabetes Association's 83rd Scientific Sessions; June 23, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(supplement_1):846-P. doi: 10.2337/db23-846-P
Johannes CB , Beachler DC, Layton JB , Danysh HE , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3
Danysh HE , Johannes CB , Beachler DC, Layton JB , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M , Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4
Beachler DC, Taylor DH, Anthony MS , Yin R, Li L, Saltus CW , Li Lin, Shaunik A, Walsh KE, Rothman KJ , Johannes CB , Aroda VR, Carr W, Goldberg P, Accardi A, O'Shura JS, Sharma K, Juhaeri J, Lanes S, Wu C. Response to letter to the editor regarding “Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data” . Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):110-1. doi: 10.1002/pds.5376
Beachler DC, Taylor DH, Anthony MS , Yin R, Li L, Saltus CW , Li Lin, Shaunik A, Walsh KE, Rothman KJ , Johannes CB , Aroda VR, Carr W, Goldberg P, Accardi A, O'Shura JS, Sharma K, Juhaeri J, Lanes S, Wu C. Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data . Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):918-26. doi: 10.1002/pds.5257
Johannes C , Layton JB , Beachler DM, Ziemiecki RM , Li L, Danysh HE , Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A . Risk of acute kidney injury in real-world use of dapagliflozin . Presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Johannes C , Layton JB , Beachler DC, Ziemiecki RM , Li L, Danysh HE , Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A . Risk of severe complications of urinary tract infection in real-world use of dapagliflozin . Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Beachler DC, Taylor DH, Anthony MS , Yin R, Li L, Saltus CW , Li Lin, Shaunik A, Walsh KE, Lanes S, Rothman KJ , Johannes C , Aroda V, Carr W, Goldberg P, Accardi A, Shane O'Shura J, Sharma K, Juhaeri J, Wu C. Development and validation of a machine learning algorithm to identify anaphylaxis in US administrative claims data . Presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Danysh HE , Gilsenan A , Beachler DC, Kaye JA, Garcia-Albeniz X , Schmid R, Hunter S, Hunt PR, Aguado J , Calingaert B , Layton JB , Gutierrez L . Validation of breast cancer and bladder cancer among patients with type 2 diabetes mellitus in Medicare: a pilot study . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Layton JB , Zhou CK, Danysh HE , Bleachler DC, Ziemiecki R , Dinah J, Yin R, Calingaert B , Hunt PR, Gilsenan AW , Johannes CW . Identifying cohorts of patients with type 2 diabetes mellitus initiating dapagliflozin in three data sources . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia de Albeniz X , Hunt PR, Gilsenan A , Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Danysh HE , Layton B , Beachler DC, Arana A , Pladevall-Vila M , Schmid R, Calingaert B , Ziemiecki R , Hunt PR, Gilsenan A , Johannes C . Validation of acute outcomes among patients with type 2 diabetes mellitus in Medicare: a pilot study . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.
Zhou CK, Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia-Albeniz X , Gangemi K, Yin R, Ruzafa JC, Gilsenan A , Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864
Gilbertson DT, Rothman KJ , Chertow GM, Bradbury BD, Brookhart MA, Liu L, Winkelmayer WC, Sturmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB. Excess deaths attributable to influenza-like illness in the ESRD population . J Am Soc Nephrol. 2019 Feb;30(2):346-53. doi: 10.1681/ASN.2018060581
Saigi-Morgui N , Quteineh L, Bochud PY, Crettol S, Kutalik Z, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccal PM, Pascual M, Eap CB, Swiss Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation . Pharmacogenomics J. 2019 Feb;19(1):53-64. doi: 10.1038/s41397-017-0001-5
Gutierrez L , Beachler DC, Overbeek J, McQuay L, Yin R, Kuiper J, McGrath L, Jemison J, Houben E, Lanes S, Gilsenan A , Herrings R. Characteristics of new users of dapagliflozin and other antidiabetic drugs: United States, United Kingdom, and the Netherlands . Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):128.
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ , Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform . J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232
Gil M, Romio S, Scotti L, Leal I, Masclee GMC, Schmedt N, Varas-Lorenzo C, Pladevall-Vila M , Smits MM, Bezemer I, Seeger JD, de Beradis G, Pecchioli S, Trifiro G, McGrogan A, Rijnbeek P, Sturkenboom M. Risk of hemorrhagic stroke associated with non-insulin blood glucose lowering drugs. Results from the SAFEGUARD project . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):428-9.
Masclee GMC, Leal I, Scotti L, De Berardis G, Bezemer I, Gil M, McGrogan A, Schmedt N, Seeger JD, Trifiro G, Pecchioli S, Pladevall-Vila M , Smits MM, Rijnbeek P, Sturkenboom M, Romio SA. Use of non-insulin blood glucose lowering drugs and the risk of acute pancreatitis . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):246-7.
Gilbertson DT, Bradbury BD, Wetmore JB, Weinhandl ED, Monda KL, Liu J, Brookhart MA, Gustafson SK, Roberts T, Collins AJ, Rothman KJ . Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders . Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):269-77. doi: 10.1002/pds.3922
Vinceti M, Malagoli C, Rothman KJ , Rodolfi R, Astolfi G, Calzolari E, Puccini A, Bertolotti M, Lunt M, Paterlini L, Martini M, Nicolini F. Risk of birth defects associated with maternal pregestational diabetes . Eur J Epidemiol. 2014 Jun;29(6):411-8.